Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Valneva ( (VALN) ) is now available.
On February 3, 2026, Valneva SE and Brazil’s Instituto Butantan announced the launch of a Pilot Vaccination Strategy in ten Brazilian municipalities using Valneva’s single-shot chikungunya vaccine IXCHIQ®. Under the program, which follows IXCHIQ’s April 2025 marketing approval by ANVISA for adults in Brazil, up to 500,000 donated doses will be used to reach 20%–40% coverage among adults aged 18 to 59, generating large-scale, real-world evidence on the vaccine’s effectiveness and safety in an endemic setting. The initiative, built on a longstanding technology transfer and CEPI-backed collaboration, strengthens Valneva’s positioning in emerging-markets vaccines and responds to Brazil’s heavy chikungunya burden—over one million cases between January 2019 and July 2024—potentially enhancing the product’s public-health profile and supporting future policy and market uptake in Latin America and other affected regions.
The most recent analyst rating on (VALN) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s overall stock score reflects significant financial challenges, including negative profitability and cash flow issues. While technical indicators show neutral momentum, and the earnings call highlighted some positive developments, the company’s high leverage and ongoing losses weigh heavily on the score. Promising clinical advancements provide potential for future growth but are not enough to offset current financial concerns.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines targeting infectious diseases with unmet medical needs. The group applies multiple vaccine modalities to deliver first-, best- or only-in-class solutions, currently markets three proprietary travel vaccines, and reinvests revenues to advance a pipeline that includes the only Lyme disease vaccine candidate in advanced clinical development with Pfizer and a leading tetravalent Shigella vaccine candidate, alongside other programs addressing global public health threats.
Average Trading Volume: 20,029
Technical Sentiment Signal: Buy
Current Market Cap: $790.4M
For a thorough assessment of VALN stock, go to TipRanks’ Stock Analysis page.